Eli Lilly EBITDA 2012-2026 | LLY

Eli Lilly EBITDA for the quarter ending March 31, 2026 was $8.960B, a 72.36% increase year-over-year.

  • Eli Lilly 2025 EBITDA was 28.299B, a 92.96% increase from 2024.
  • Eli Lilly 2024 EBITDA was 14.666B, a 83.66% increase from 2023.
  • Eli Lilly 2023 EBITDA was 7.985B, a 7.68% decline from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Eli Lilly EBITDA 2012-2026 | LLY

  • Eli Lilly 2025 EBITDA was 28.299B, a 92.96% increase from 2024.
  • Eli Lilly 2024 EBITDA was 14.666B, a 83.66% increase from 2023.
  • Eli Lilly 2023 EBITDA was 7.985B, a 7.68% decline from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B